Description: Evolus Inc is engaged in providing physicians and their patients with expanded choices in medical aesthetic treatments and procedures. Its product candidate is an injectable formulation of a 900 kDa Botulinum toxin Type A complex.
Home Page: www.evolus.com
EOLS Technical Analysis
520 Newport Center Drive
Newport Beach,
CA
92660
United States
Phone:
949 284 4555
Officers
| Name | Title |
|---|---|
| Mr. David Moatazedi | Pres, CEO & Director |
| Dr. Rui Avelar C.CFP, Dip.SportMed, M.D. | Chief Medical Officer and Head of R&D |
| Ms. Sandra Beaver | Chief Financial Officer |
| Mr. David K. Erickson | VP of Investor Relations |
| Mr. Jeffrey J. Plumer | Gen. Counsel |
| Mr. Kurt Knab | VP of Sales |
| Ms. Crystal Muilenburg | Chief Marketing Officer |
| Ms. Jessica Novak | Sr. VP of HR |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 14.6487 |
| Price-to-Sales TTM: | 2.9729 |
| IPO Date: | 2018-02-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 213 |